Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa first-in-human trial of BNT329 in CA19-9-positive advanced solid tumors
2025-522613-26-00Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of BNT329 in pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA), transitional cell carcinoma (TCC) and 6 more (4 arms), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, Safety events and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
BNT329
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)transitional cell carcinoma (TCC)colorectal adenocarcinomaEsophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on 2025-522613-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522613-26-00.